These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3103382)

  • 1. Critical role of MAO inhibition in Parkinson's disease.
    Knoll J
    Adv Neurol; 1987; 45():107-10. PubMed ID: 3103382
    [No Abstract]   [Full Text] [Related]  

  • 2. MAO-B inhibitors in Parkinson's disease.
    Olanow CW
    Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
    [No Abstract]   [Full Text] [Related]  

  • 3. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB; Finberg JP
    Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

  • 7. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 9. [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
    Kassubek J; Büttner T; Reichmann H; Riederer P; Schulz JB; Wüllner U; Csoti I
    Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S34-6. PubMed ID: 20195940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
    Hamaue N; Minami M; Terado M; Hirafuji M; Endo T; Machida M; Hiroshige T; Ogata A; Tashiro K; Saito H; Parvez SH
    Neurotoxicology; 2004 Jan; 25(1-2):205-13. PubMed ID: 14697895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
    Li XM; Juorio AV; Paterson IA; Boulton AA
    J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
    [No Abstract]   [Full Text] [Related]  

  • 13. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
    Müller T; Riederer P; Grünblatt E
    J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease.
    Imke S
    Adv Nurse Pract; 1998 Jan; 6(1):24-8. PubMed ID: 9495941
    [No Abstract]   [Full Text] [Related]  

  • 15. [Neuroprotective and neurorestorative therapy in Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
    Cohen G
    J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
    Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
    Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.